Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Found 348 Results
First Patient Enrolled in Palatin’s Phase 2 study of PL8177 in Ulcerative Colitis Trial
October 20, 2022
Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)
October 17, 2022
Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results
October 13, 2022
Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference
September 29, 2022
Palatin to Participate in Ladenburg Thalmann Healthcare Conference
September 29, 2022
Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
September 22, 2022
Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022
September 19, 2022
Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis
September 8, 2022
Palatin Announces Intent to Effect Reverse Stock Split
August 19, 2022
Page 11 of 35